文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

靶向蛋白质组学分析识别危重型COVID-19患者的新型结局生物标志物

Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients.
PubMed 文献 · Crit Care Explor · 2020-08-24
一句话结论对ICU的COVID-19阳性患者血浆行靶向蛋白质组学检测,可100%区分阳性与阴性/健康对照,6种蛋白在ICU第1天即可极准确预测死亡。

该研究在三级ICU对疑似SARS-CoV-2感染患者于预定ICU日采血,用邻近延伸法测定1161种血浆蛋白浓度,并与年龄性别匹配的健康对照及ICU内COVID-19阴性患者比较。COVID-19阳性患者病死率40%,蛋白质组以白介素、趋化因子及与淋巴细胞相关微粒/细胞碎片有关的膜受体为主。特征分类可100%准确区分阳性患者与健康对照及阴性ICU患者;基于血浆蛋白质组谱在ICU第1天(准确率92%)和第3天(准确率83%)预测死亡,最终筛选出6种蛋白,第1天测定时对死亡的分类性能极佳(曲线下面积=1.0;P=0.007)。

要点

  • COVID-19阳性ICU患者病死率40%,靶向蛋白质组学特征分类区分阳性与健康对照及阴性ICU患者的准确率均为100%。
  • 血浆蛋白质组谱在ICU第1天预测死亡的准确率为92%,第3天为83%。
  • 6种蛋白(CMRF-35样分子、白介素受体-12亚基B1、CD83、家族序列相似性3、胰岛素样生长因子1受体、视蛋白)在ICU第1天测定时对死亡分类的曲线下面积=1.0,P=0.007。
  • COVID-19蛋白质组以白介素、趋化因子及与淋巴细胞相关微粒/细胞碎片有关的膜受体为主。

适用人群与场景

  • 入住三级ICU、经标准化医院筛查方法怀疑感染SARS-CoV-2的患者,血样采集至ICU第3天检测确认阴性(COVID-19阴性)或阳性患者至ICU第10天。
  • 年龄和性别匹配的健康对照受试者,以及COVID-19阳性或阴性的ICU患者。
  • 各队列基线均衡,唯一例外是COVID-19阳性患者双侧肺炎发生率高于COVID-19阴性患者。

研究设计与关键结果

  • 研究设计:对危重型COVID-19患者行靶向蛋白质组学检测,采用邻近延伸法测定血浆中1161种蛋白浓度,采血时间为预定的ICU日。
  • COVID-19阳性ICU患者病死率为40%。
  • 特征选择识别出的最优蛋白可从健康对照和COVID-19阴性ICU患者中识别COVID-19阳性ICU患者,分类准确率均为100%。
  • COVID-19蛋白质组以白介素和趋化因子为主,以及若干与淋巴细胞相关微粒和/或细胞碎片有关的膜受体。
  • 基于血浆蛋白质组谱预测COVID-19阳性患者死亡:ICU第1天准确率92%,ICU第3天准确率83%。
  • 预后蛋白 narrowed down 至6种(CMRF-35样分子、白介素受体-12亚基B1、CD83、家族序列相似性3、胰岛素样生长因子1受体、视蛋白),在ICU第1天测定时对死亡分类性能极佳,曲线下面积=1.0,P=0.007。

证据类型、等级与局限

  • 证据类型:观察性队列研究(原文未明确标注研究类型,据摘要描述为对ICU患者行靶向蛋白质组学分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Coronavirus disease 2019 patients admitted to the ICU have high mortality. The host response to coronavirus disease 2019 has only been partially elucidated, and prognostic biomarkers have not been identified. We performed targeted proteomics on critically ill coronavirus disease 2019 patients to better understand their pathophysiologic mediators and to identify potential outcome markers.

DESIGN: Blood was collected at predetermined ICU days for proximity extension assays to determine the plasma concentrations of 1,161 proteins.

SETTING: Tertiary care ICU and academic laboratory.

SUBJECTS: All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome coronavirus 2, using standardized hospital screening methodologies, had blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative) or until ICU day 10 if the patient positive (coronavirus disease 2019 positive).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Age- and sex-matched healthy control subjects and ICU patients who were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients suffered bilateral pneumonia more frequently than coronavirus disease 2019 negative patients. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. Feature selection identified the top performing proteins for identifying coronavirus disease 2019 positive ICU patients from both healthy control subjects and coronavirus disease 2019 negative ICU patients (classification accuracies 100%). The coronavirus disease 2019 proteome was dominated by interleukins and chemokines, as well as several membrane receptors linked to lymphocyte-associated microparticles and/or cell debris. Mortality was predicted for coronavirus disease 2019 positive patients based on plasma proteome profiling on both ICU day 1 (accuracy 92%) and ICU day 3 (accuracy 83%). Promising prognostic proteins were then narrowed down to six, each of which provided excellent classification performance for mortality when measured on ICU day 1 CMRF-35-like molecule, interleukin receptor-12 subunit B1, cluster of differentiation 83 [CD83], family with sequence similarity 3, insulin-like growth factor 1 receptor and opticin; area-under-the-curve =1.0; p = 0.007).

CONCLUSIONS: Targeted proteomics with feature classification easily distinguished both healthy control subjects and coronavirus disease 2019 tested negative ICU patients from coronavirus disease 2019 tested positive ICU patients. Multiple proteins were identified that accurately predicted coronavirus disease 2019 tested positive patient mortality.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Fraser DD, Cepinskas G, Patterson EK, et al. Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients. Crit Care Explor. 2020. PMID: 32904064. doi:10.1097/CCE.0000000000000189

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。